KPV Peptide and the KLOW Blend: A Research Review of the α-MSH C-Terminal Tripeptide, Its Receptor-Independent NF-κB Mechanism and the Catalogue Terminology Behind "klow stack", "klow blend" and "klow protocol" Labels

Peptide Insider Research Desk · 12 min read · Last updated 14 September 2026

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), the fragment that retained the parent hormone's anti-inflammatory signalling in early fragment-mapping studies while losing its pigmentary activity [1,2]. It is also the least-discussed component of the four-part klow blend peptide preparation (GHK-Cu, BPC-157, TB-500 and KPV) that appears in research catalogues under the labels klow peptides, klow stack peptide and klow peptide blend. This review examines KPV's chemistry and its receptor-independent NF-κB mechanism, places it in the context of the other three components, and interprets the catalogue and forum terminology honestly, including the strings klow protocol, klow stack peptides and klow peptide stack, which describe a labelled preparation and not any published experimental scheme. All content is provided strictly for research reference.

Introduction

Most attention paid to the klow blend peptide preparation concentrates on its three larger components, each of which already has a dedicated review on this site: the copper tripeptide GHK-Cu, the gastric pentadecapeptide BPC-157 and the thymosin β4 fragment TB-500. KPV is different in kind. It is a three-residue fragment of a pituitary hormone, it carries no metal, it has no receptor of its own in the classical sense, and its literature sits in mucosal immunology rather than wound repair [2,4,5]. Because the existing KLOW blend review treated the four components at equal depth, this companion article gives KPV the mechanistic treatment it lacked and, at the same time, resolves the terminology questions that dominate search behaviour around the blend ("what is in klow peptide", "klow stack vs blend", "klow protocol").

Biological background: α-MSH and its fragments

α-MSH is a 13-residue peptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) cleaved from pro-opiomelanocortin (POMC). Its pigmentary and many of its immunological effects are mediated by melanocortin receptors (MC1R–MC5R), G-protein-coupled receptors that raise intracellular cAMP [2]. The core pharmacophore for receptor binding is the central His-Phe-Arg-Trp tetrapeptide; the C-terminal Lys-Pro-Val tripeptide lies outside it [2].

In 1989 Hiltz and Lipton reported that the isolated C-terminal tripeptide (α-MSH(11–13), i.e. KPV) reduced picryl-chloride-induced ear swelling in mice in a concentration-related manner while lacking the structural requirements for melanotropic activity [1]. That observation separated the anti-inflammatory activity of α-MSH from its pigmentary activity and launched a fragment literature that Brzoska and colleagues reviewed comprehensively in Endocrine Reviews in 2008 [2]. The same review covers the closely related tripeptide KdPT (Lys-D-Pro-Thr), which shares the anti-inflammatory profile and is sometimes confused with KPV in catalogue listings [2].

Structure and mechanism

Sequence and physical chemistry. KPV is H-Lys-Pro-Val-OH (C₁₆H₃₀N₄O₄, monoisotopic mass 342.2 Da). It carries a basic lysine side chain and a proline that constrains the backbone; the C-terminus is a free acid in most catalogue material, whereas in native α-MSH the valine is amidated. Vendors sometimes list the amidated or acetylated forms without distinction, which matters for analytical identity checks.

Receptor-independent NF-κB inhibition. Two lines of evidence indicate that KPV does not require a melanocortin receptor. Mandrika, Muceniece and Wikberg showed in RAW 264.7 macrophage-like cells that α-MSH(11–13) neither bound MC1R nor raised cAMP, yet still inhibited LPS/IFN-γ-induced nitric oxide production and NF-κB nuclear translocation, in contrast to full-length α-MSH, which acted through both cAMP-dependent and cAMP-independent routes [6]. Kannengiesser and colleagues later observed that KPV retained its protective effect in MC1R-deficient (MC1R^e/e) mice with DSS colitis, arguing that the classical receptor is dispensable in vivo as well [3].

PepT1-mediated cellular uptake. Dalmasso and colleagues identified the di/tripeptide transporter PepT1 (SLC15A1) as the entry route for KPV into intestinal epithelial cells (Caco2-BBE, HT29-Cl.19A) and Jurkat T cells. Radiolabelled KPV uptake was competed by the PepT1 substrate Gly-Leu, and nanomolar KPV inhibited NF-κB and MAP kinase activation and pro-inflammatory cytokine secretion; the effect was diminished when PepT1 was inhibited or absent [4]. Because PepT1 is induced in the colon during inflammation, this transporter dependence has been proposed as a mechanism for preferential accumulation in inflamed tissue [4].

Nuclear import blockade. Land, working in 16HBE14o- human bronchial epithelial cells, reported that KPV enters the nucleus and interacts with the p65 RelA subunit of NF-κB at the binding site for importin-α3, preventing p65 nuclear translocation, stabilising IκBα and reducing IL-8, eotaxin and MMP-9 output after TNF-α or RSV stimulation [5]. In the same system, the receptor-dependent action of full-length α-MSH ran through MC3R, the dominant melanocortin receptor in that epithelium, giving two mechanistically distinct anti-inflammatory routes for the parent peptide and its fragment [5].

Nomenclature and catalogue variants

Search and catalogue strings around this preparation fall into three families: component-level names, blend/stack terminology and forum or question phrasing. The table interprets each honestly.

Catalogue / search string	Family	Interpretation
klow blend peptide, klow peptide blend, klow peptides	Blend label, word-order variants	Four-component preparation (GHK-Cu, BPC-157, TB-500, KPV) sold as a single vial; "peptides" in the plural reflects the multi-component nature.
klow stack peptide, klow stack peptides, klow peptide stack	"Stack" terminology	Forum-derived synonym for the same preparation. "Stack" implies co-formulation in one vial, not a separately studied combination; no publication has tested it.
peptides klow, peptide klow	Inverted word order	Search-engine artefacts of the blend label; identical referent.
klow protocol	Forum term	Describes user-generated usage schemes on forums. No peer-reviewed protocol exists and this review does not provide one; the term has no scientific referent.
kpv 10mg	Vial-size attribute	Catalogue quantity of the single tripeptide, typically lyophilised. A quantity label, not a research design parameter.
klow peptide reddit	Forum-source string	Discussion-thread searches; threads commonly conflate KPV with KdPT and misreport the origin of the blend's blue colour (see FAQ).
what is in klow peptide, what is klow peptide used for	Question phrasing	Answered verbatim in the FAQ below from the component literature.
KdPT, Lys-D-Pro-Thr	Related tripeptide	A distinct α-MSH-derived tripeptide with a D-proline and threonine; not KPV, though both are reviewed together [2].

Evidence by research domain

Domain	Model(s)	Principal observations	Key refs
Cutaneous inflammation	Picryl-chloride ear swelling, mouse	Concentration-related reduction of swelling by α-MSH(11–13)	[1,2]
Intestinal inflammation	DSS and TNBS colitis; CD45RBhi transfer colitis; MC1Re/e mice	Reduced histological inflammation, MPO activity and cytokine mRNA; effect retained without MC1R	[3,4]
Macrophage signalling	RAW 264.7 cells	Inhibition of NO production and NF-κB translocation without MC1R binding or cAMP rise	[6]
Airway epithelium	16HBE14o- cells	Nuclear import blockade of p65; reduced IL-8, eotaxin, MMP-9	[5]
Antimicrobial activity	S. aureus, C. albicans in vitro	Reported growth inhibition [7]; anti-Candida effect of KPV not reproduced by an independent group [8]	[7,8]
Targeted delivery	HA-functionalised nanoparticles, DSS colitis	Colon-targeted KPV nanoparticles reduced colitis severity in mice	[9]

Intestinal inflammation models

The colitis literature is the most developed domain for KPV. Kannengiesser and colleagues reported earlier body-weight recovery, fewer inflammatory infiltrates and lower colonic myeloperoxidase activity in DSS colitis and in CD45RB^hi transfer colitis, with all MC1R-deficient animals surviving DSS exposure under KPV [3]. Dalmasso and colleagues, in DSS and TNBS models, observed reduced incidence and histological severity of colitis and lower pro-inflammatory cytokine mRNA, and tied these effects to PepT1 transport [4]. Xiao and colleagues subsequently loaded KPV into hyaluronic-acid-functionalised polymeric nanoparticles embedded in a hydrogel, achieving colon-restricted release and reduced colitis in mice, a formulation study that treats KPV as a payload rather than a free peptide [9].

Cell-signalling studies

Across macrophage, T-cell, intestinal epithelial and bronchial epithelial systems, the convergent readout is inhibition of NF-κB activity: reduced p65 nuclear translocation, stabilised IκBα and lower downstream cytokine or chemokine output [4,5,6]. The mechanistic details differ, with PepT1 uptake emphasised in the gut [4] and importin-α3 competition in the airway [5], but neither requires a melanocortin receptor, which distinguishes KPV from its parent hormone and from the melanocortin agonists reviewed in the melanocortin family review.

Antimicrobial reports and a reproducibility caveat

Cutuli and colleagues reported that α-MSH and KPV reduced Staphylococcus aureus colony formation and Candida albicans viability and germ-tube formation across a wide concentration range, and proposed a cAMP-linked mechanism in the microbe [7]. A 2009 letter by Rauch and colleagues reported that the anti-Candida effect could not be reproduced in their growth-inhibition assays, with no effect observed for KPV [8]. The antimicrobial claim should therefore be regarded as unresolved.

KPV alongside the other three components

The three companions in the preparation act through unrelated chemistry. GHK-Cu is a copper(II) complex of Gly-His-Lys; Freedman and colleagues characterised the 1:1 complex in solution, with equatorial nitrogen coordination involving the histidyl imidazole, and it is this copper coordination sphere that gives concentrated GHK-Cu solutions their blue-violet colour [10]. Pickart and Margolina's 2018 review summarises its reported gene-expression and extracellular-matrix effects [11]. BPC-157 is a 15-residue gastric-juice-derived pentadecapeptide studied mainly in rodent injury models; Sikiric and colleagues review its proposed brain–gut and vascular mechanisms [12]. TB-500 corresponds to the actin-binding region of thymosin β4, the 43-residue G-actin-sequestering protein reviewed by Goldstein, Hannappel and Kleinman [13].

Two points follow. First, when the four are co-formulated, KPV is the only component whose principal mechanism is intracellular transcription-factor inhibition rather than extracellular or receptor-level action. Second, no study has measured whether the copper centre of GHK-Cu, the free lysine of KPV or the histidines of BPC-157 interact chemically in the same solution; questions of compatibility are open, and the existing evidence for each constituent should not be summed as if it were evidence for the mixture.

Limitations and research considerations

• No combination data. Every citation in this review concerns a single compound; the four-component preparation has not been studied.
• Preclinical scope. KPV evidence rests on cell lines and rodent colitis and dermatitis models; no controlled human trial has been published.
• Form ambiguity. Free-acid, amidated and acetylated KPV are not always distinguished in catalogues; identity should be confirmed analytically (HPLC, mass spectrometry).
• Contested antimicrobial data. The anti-Candida finding failed independent replication [8].
• Terminology drift. "Stack", "blend" and "protocol" are commercial and forum terms without scientific definitions.

Where to source for research

KPV is available as a single lyophilised tripeptide (commonly listed as kpv 10mg) and as a constituent of the four-component preparation from several research-grade suppliers. Short Chain Aminos lists single-compound and blend formats with batch documentation. BioPep, Catalyst Research and Apex Research Services also carry research-grade material. For a blend, laboratories should request a certificate of analysis that states each component's identity and purity separately, since a single HPLC trace for a four-peptide mixture cannot verify the ratio without component standards. General evaluation criteria are set out in our guide to evaluating research peptide suppliers.

Frequently asked research questions

What is in klow peptide?

The label denotes a four-component preparation: GHK-Cu (a copper tripeptide), BPC-157 (a 15-residue gastric pentadecapeptide), TB-500 (a thymosin β4 fragment) and KPV (the Lys-Pro-Val C-terminal tripeptide of α-MSH). Component ratios are set by the vendor and vary; the acronym is a commercial coinage with no chemical or regulatory definition.

What is klow peptide used for?

In the research literature, nothing has been published on the four-component mixture. Each component has been investigated separately: KPV in rodent colitis and cell-signalling models, GHK-Cu in extracellular-matrix and gene-expression studies, BPC-157 in rodent injury models and thymosin β4 in actin-dynamics research. These separate contexts do not constitute evidence for the blend.

Is a klow stack peptide the same as a klow peptide blend?

Yes. "Stack" is forum-derived and "blend" is catalogue-derived, but both refer to the same co-formulated four-peptide vial. Neither term implies that the combination has been tested experimentally; the words describe how the material is packaged, not how it behaves.

What does "klow protocol" mean in catalogue and forum listings?

It refers to user-generated usage schemes circulated on forums. There is no peer-reviewed protocol for the preparation, no regulatory approval and no published experimental design; this review does not provide one. The phrase has no scientific referent and should not be read as a research method.

Why do klow peptide reddit threads describe the blend as blue?

The colour comes from GHK-Cu. Copper(II) coordinated by the glycyl amine, histidyl imidazole and backbone nitrogens absorbs in the visible region, so concentrated solutions appear blue to violet [10]. KPV, BPC-157 and TB-500 are colourless; the intensity of blue reflects the copper-peptide content, not potency.

What does "kpv 10mg" denote?

A catalogue quantity: 10 milligrams of lyophilised Lys-Pro-Val in a single vial. It is a packaging attribute used for pricing and inventory. It carries no information about the form (free acid, amide or acetylated) or the purity, both of which must come from the certificate of analysis.

Does KPV act through melanocortin receptors?

The available evidence says no. In macrophage cells, KPV neither bound MC1R nor raised cAMP yet still suppressed NF-κB [6]; in MC1R-deficient mice, its protective effect in colitis persisted [3]. Proposed mechanisms are PepT1-mediated uptake and blockade of p65 nuclear import [4,5].

Works Cited

1. Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB J. 1989;3(11):2282-2284. doi:10.1096/fasebj.3.11.2550304. PMID 2550304.
2. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. doi:10.1210/er.2007-0027. PMID 18612139.
3. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. doi:10.1002/ibd.20334. PMID 18092346.
4. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026. PMID 18061177.
5. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. PMC3403564.
6. Mandrika I, Muceniece R, Wikberg JE. Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of action. Biochem Pharmacol. 2001;61(5):613-621. PMID 11239505.
7. Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-239. PMID 10670585.
8. Rauch I, et al. Letter to the editor: antimicrobial activity of α-MSH peptides against Candida albicans not reproduced. J Leukoc Biol. 2009. PMID 19092131.
9. Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Mol Ther. 2017;25(7):1628-1640. PMC5498804.
10. Freedman JH, Pickart L, Weinstein B, Mims WB, Peisach J. Structure of the glycyl-L-histidyl-L-lysine-copper(II) complex in solution. Biochemistry. 1982;21(19):4540-4544. PMID 6291585.
11. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID 29986520.
12. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID 27138887.
13. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. PMID 16099219.

Research use only. This article summarises published preclinical and in-vitro literature for research reference. KPV and the four-component preparation discussed are research chemicals, not for human or veterinary use. No usage, administration or protocol guidance is given or implied. All content is provided strictly for research reference.

Related reviews: KLOW Peptide Blend · GHK-Cu · BPC-157 / TB-500 Blend · Melanocortin Agonist Family